Anteromedial Extension and Early Facial Nerve Outcome After Retrosigmoid Vestibular Schwannoma Resection: A Retrospective Cohort Study

Inside the deep, narrow space where the brain meets the inner ear lies a delicate balance between a tumor and a nerve. This space, known as the cerebellopontine angle, is the home of the vestibular schwannoma, a slow-growing, benign tumor that arises from the hearing and balance nerves. While these growths are not cancerous, their location makes them a significant challenge for surgeons. The primary goal of removing such a tumor is not just to eliminate the mass, but to preserve the function of the facial nerve, which runs directly alongside it. If this nerve is damaged during surgery, a patient can lose the ability to move one side of their face, a consequence that often weighs more heavily on their quality of life than the tumor itself. For decades, doctors have relied on the size of the tumor to predict how difficult the surgery will be. They measure how wide the tumor is or calculate its total volume, assuming that a larger mass is simply harder to remove without injury. However, this approach treats the tumor as a uniform blob, ignoring the fact that two tumors of the exact same size can grow in very different directions, potentially pressing against the nerve in ways that a simple measurement of width cannot reveal.

A team of researchers at Charles University and Motol University Hospital in Prague set out to test whether the direction of a tumor's growth matters just as much as its size. They focused on a specific type of growth called anteromedial extension, which describes a tumor pushing forward and inward toward the brainstem and the front of the inner ear space. To investigate this, the researchers looked back at the medical records of 129 adults who had undergone surgery to remove these tumors between 2019 and 2023. Every patient had a preoperative magnetic resonance imaging scan, which the team analyzed with great care. Two independent reviewers, who did not know the surgical outcomes, measured the tumors in three ways: they calculated the total volume of the tumor, measured its widest point, and measured how far the tumor extended toward the front and center of the skull base. They then compared these measurements against the actual results of the surgery, specifically looking at whether the facial nerve was accidentally cut and how well the patients' faces functioned immediately after the operation.

The study confirmed what was already suspected: the size of the tumor is a powerful predictor of risk. Larger tumors, whether measured by volume or width, were indeed associated with a higher chance of the facial nerve being cut or the patient experiencing significant weakness immediately after surgery. The researchers found that the new measurement of directional growth was strongly linked to these standard size measurements; a tumor that was large in volume was also likely to have a large directional extension. This meant that the new metric was not a completely separate factor but rather a reflection of the overall mass. However, when the researchers looked closer, they discovered that the direction of growth provided a different kind of information. While the new measurement did not replace the need for knowing the total volume of the tumor, it offered a way to refine the risk assessment for patients with the largest, most advanced tumors.

In the group of patients with the most advanced tumors, classified as the highest stage of disease, the direction of growth became a critical differentiator. For these patients, the researchers identified a specific threshold: when the tumor extended more than 8 millimeters toward the front and center, the risk of severe facial weakness immediately after surgery jumped significantly. In this specific subgroup, patients with a smaller directional extension had a much lower rate of severe weakness compared to those with the larger extension. This finding suggests that within the category of large tumors, some are simply more dangerous to operate on than others, not because they are bigger, but because they are growing into a more precarious position relative to the facial nerve. The study did not find that this directional measurement was better than calculating the total volume for predicting outcomes across all patients, but it did show that it could help surgeons identify a particularly high-risk group among those who already had large tumors.

The researchers were careful to note that this 8-millimeter threshold was derived from their own data and requires further testing in other groups of patients before it can be used as a standard rule in hospitals. They also emphasized that this measurement is a simple tool that can be taken from routine MRI scans without the need for complex, specialized imaging techniques. It does not replace the detailed volume calculations that surgeons already use, but it acts as a quick, practical check that highlights tumors growing in a specific, unfavorable direction. By adding this simple directional check to the existing assessment of tumor size, doctors may be better equipped to counsel patients about the risks of surgery and to plan their approach to preserving the facial nerve. The study concludes that while the total amount of tumor remains the most important factor, understanding where that tumor is growing provides a clearer picture of the surgical landscape, helping to distinguish between a large tumor that is manageable and one that poses a particularly steep challenge to the delicate nerve running alongside it.